Results for: Medical Products

Cardinal Health, a leading distributor of pharmaceuticals and medical products, announced strong first-quarter fiscal year 2025 results, highlighting robust performance in its Pharmaceutical and Specialty Solutions segment and leading to an upward revision of its fiscal year outlook. Revenue decreased by 4% to $52.3 billion, but increased by 15% when excluding the impact of a previously communicated large customer contract expiration. The company also raised its non-GAAP diluted earnings per share guidance for fiscal 2025 to $7.75 to $7.90, demonstrating confidence in its future performance.

Cardinal Health (CAH) is scheduled to report its fourth-quarter fiscal 2024 results on August 14th. Analysts expect strong growth, driven by rising demand for pharmaceutical products and a focus on specialty solutions. The company’s recent acquisition of Specialty Networks and its new distribution center in South Carolina are also expected to contribute to positive results. However, the Zacks model does not predict a significant earnings beat.